Edwards Lifesciences Corporation revised earnings guidance for the full year 2024. For the year, the company now expects full-year 2024 sales growth to be at the high end of the prior guidance of 8% to 10% and $6.3 billion to $6.6 billion.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
87 USD | -1.11% | -3.70% | +14.10% |
May. 23 | Some of the biggest splits in Corporate America | RE |
May. 22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.10% | 53.02B | |
+7.60% | 223B | |
+11.47% | 195B | |
+18.77% | 144B | |
+29.99% | 111B | |
+2.32% | 65.19B | |
+2.68% | 50.28B | |
+6.27% | 44.15B | |
+1.76% | 36.45B | |
+20.61% | 31.33B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024